Iloprost for severe Raynaud's phenomenon and ischaemic ulcers related with systemic diseases;Iloprost en el fenómeno de Raynaud grave y las úlceras isquémicas de las enfermedades sistémicas

Medicina Clinica

Volumn 122, Issue 13, 2004, Pages 501-504

  García Hernández, Francisco José ^a   Ocaña Medina, Celia ^a   Mateos Romero, Luis ^a   Molinillo López, Juan ^a   Arias Zambrano, Andrés ^a   González León, Rocío ^a   Sánchez Román, Julio ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b NONE   (Spain)

Author keywords

Autoimmune systemic diseases; Iloprost; Raynaud's phenomenon

Indexed keywords

ILOPROST;

ABDOMINAL PAIN; ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTHRALGIA; ARTICLE; ASTHENIA; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLUSHING; FOOT PAIN; HEADACHE; HUMAN; HYPOTENSION; LEG ULCER; MALE; MYALGIA; NAUSEA; PAIN; RAYNAUD PHENOMENON; SCLERODERMA; VOMITING;

EID: 2442439831     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13060173     Document Type: Article

References (22)

1. Block JA, Sequeira W. Raynaud's phenomenon. Lancet 2001;357:2042-8.
2. Wigley F M. Raynaud's phenomenon. N Engl J Med 2002;347:1001-8.
3. Román Ivorra JA, Gonzálvez Perales JL, Fernández Carballido C, Grana J, Torres MJ. Prevalence of Raynaud's phenomenon in general practice in the east of Spain. Clin Rheumatol 2001;20: 88-90.
4. Riera G, Vilardell M, Vaque J, Fonollosa V, Bermejo B. Prevalence of Raynaud's phenomenon in a healthy Spanish population. J Rheumatol 1993;20:66-9.
5. Grassi W, De Angelis R, Lapadula G, Leardini G, Scarpa R. Clinical diagnosis found in patients with Raynaud's phenomenon: a multicentre study. Rheumatol Int 1998;18:17-20.
6. Spencer Green G. Outcomes in primary Raynaud's phenomenon: a meta-analysis of the frequency, rates, and predictors of transition to secondary diseases. Arch Intern Med 1998;158:595-600.
7. Thompson AE, Shea B, Welch V, Fenlon D, Pope JE. Calcium channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum 2001;44:1841-7.
8. Dziadzio M, Denton CP, Smith R, Howell K, Blann A, Bowers E, et al. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 1999;42:2646-55.
9. Varela Aguilar JM, Sánchez Román J, Talegón Meléndez A, Castillo Palma MJ. Estudio comparativo de misoprostol y nifedipino en el tratamiento del fenómeno de Raynaud secundario a enfermedades sistémicas. Valoración hemodinámica mediante Doppler-dúplex. Rev Clin Esp 1997;197:77-83.
10. Torley HI, Madhok R, Capell HA, Brouwer RM, Maddison PJ, Black CM, et al. A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases. Ann Rheum Dis 1991;50: 800-4.
11. Cordioli E, Virgilio S, Ghirardi R, Martinelli M. Effects of long-term iloprost therapy on Raynaud's phenomenon in progressive systemic sclerosis. Minerva Med 1992;83:739-44.
12. Wigley FM, Wise RA, Seibold JR, McCloskey DA, Kujala G, Medsger TA Jr, et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study. Ann Intern Med 1994;120:199-206.
13. Zachariae H, Halkier Sorensen L, Bjerring P, Heickendorff L. Treatment of ischaemic digital ulcers and prevention of gangrene with intravenous iloprost in systemic sclerosis. Acta Derm Venereol 1996;76:236-8.
14. Ceru S, Pancera P, Sansone S, Sfondrini G, Codella O, De Sandre G, et al. Effects of five-day versus one-day infusion of iloprost on the peripheral microcirculation in patients with systemic sclerosis. Clin Exp Rheumatol 1997;15:381-5.
15. Scorza R, Caronni M, Mascagni B, Berruti V, Bazzi S, Micallef E, et al. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study. Clin Exp Rheumatol 2001;19:503-8.
16. Bettoni L, Geri A, Airo P, Danieli E, Cavazzana I, Antonioli C, et al. Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years. Clin Rheumatol 2002;21:244-50.
17. Rademaker M, Cooke ED, Almond NE, Beacham JA, Smith RE, Mant TG, et al. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study. BMJ 1989;298:561-4.
18. Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, et al. Iloprost and cisaprost for Raynaud's phenomenom in progressive systemic sclerosis. Cochrane Ubrary 2001, n.° 4.
19. Belch JJF, Capell HA, Cooke ED, Kirby JD, Lau CS, Madhok R, et al. Oral iloprost as a treatment for Raynaud's syndrome: a double blind multicentre placebo controlled study. Ann Rheum Dis 1995;54:197-200.
20. Wigley FM, Korn JH, Csuka ME, Medsger TA Jr, Rothfield NF, Ellman M, et al. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Arthritis Rheum 1998;41:670-7.
21. Black CM, Halkier Sorensen L, Belch JJ, Ullman S, Madhok R, Smit AJ, et al. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study. Br J Rheumatol 1998;37: 952-60.
22. Humbert M, Cabane J. Successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist bosentan. Rheumatology 2003;42:191-3.